Microparticulate Cancer Vaccines: Interpreting an Innovative Approach to Immunotherapy

Document Type

Conference Proceeding

Publication Date





Objective: To formulate a microparticulate murine breast cancer vaccine and determine the associated innate and adaptive immune responses.

Methods: Murine breast cancer cells, 4T07, were grown to confluence and subjected to lysis to prepare a whole cell lysate (WCL). The WCL was formulated with Eudragit FS 30 D, hydroxyl propyl methylcellulose acetate succinate, and bovine serum albumin. The formulation was spray dried to form vaccine microparticles. Separate formulations devoid of WCL were used to prepare placebo microparticles. Murine dendritic cells, DC2.4, were cultured and exposed to the following microparticle treatments: (a) vaccine, (b) vaccine + Poly (I:C) adjuvant, (c) placebo, (d) placebo + Poly (I:C) adjuvant (n =3 each). The stimulated cells were co-incubated with EL4.IL2 murine T-lymphocytes. The co-cultured dendritic cells were evaluated for their adaptive immune responses by evaluating the expression of CD40, CD80, CD86, MHC I, and MHC II by flow cytometry. The innate immune responses were evaluated by ELISAs to quantify the expression of IL-2, 10, 12, TNF alpha, and IFN-gamma in the co-culture supernatants.

Results: The vaccine + adjuvant Poly (I:C) treatment group was most effective in stimulating the adaptive responses. This group expressed significantly higher levels of CD40, CD80, MHC I, and MHC II when compared to the control (p

Implications: The microparticulate breast cancer vaccine is eliciting its immune responses by activating the adaptive immune pathway.




Poster presented at the American Association of Colleges of Pharmacy Annual Meeting in Chicago, Illinois, July 2019.

Abstract is published in American Journal of Pharmaceutical Education: Volume 83, Issue 5, Article 7654: https://www.ajpe.org/doi/full/10.5688/ajpe7654

This document is currently not available here.

Additional Files